Navigation Links
Henry Ford Hospital: Unique Patient Study -- No Informed Consent
Date:5/8/2009

DETROIT, May 8 /PRNewswire/ -- Henry Ford Hospital is embarking on an unusual study intending to reduce brain damage or death of patients resulting from prolonged seizures before arriving at the hospital.

But because the patients are unconscious during the seizure, they will not be able to provide informed consent to participate in the study.

The Food and Drug Administration created regulations for research to be performed during emergency conditions without informed consent of the participant. Once patients awaken from the seizure their consent will be sought to continue in the study.

The study will involve patients with seizures lasting longer than five minutes that are being transported by EMS. Stopping the seizure as soon as possible is important to prevent brain-damage or death. Often the underlying cause of the seizure is unknown, but some causes include previous trauma, stroke, tumor, or infection.

The study, called RAMPART, will compare an intramuscular injection of midazolam (Versed) to an intravenous (IV) dose of lorazepam (Ativan). Both drugs are better than the most common current prehospital treatment for seizure, IV diazepam (Valium). The goal is to determine if an auto-injector with midazolam can stop seizures as fast as starting an IV and giving lorazepam.

The benefits include shorter seizures, more rapid drug administration, development of an auto-injector that could be used by non-medical personnel, and avoidance of multiple IV attempts on a seizing patient.

The three-year RAMPART study is being conducted at 17 centers around the United States. It is coordinated by the University of Michigan and funded by the National Institute of Neurological Diseases and Stroke which is a part of the National Institute of Health. Wayne State University/Detroit Medical Center is also participating in RAMPART.

<
'/>"/>
SOURCE Henry Ford Hospital
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Grosse Pointes Cottage Hospital Joins Henry Ford Health System
2. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
3. Fund-Raiser for Henry Ford Hospitals Stroke Program
4. Program for Stroke Survivors and Friends Hosted by Henry Ford Hospital
5. Repligen Elects Earl Henry, M.D. to the Board of Directors
6. Michigan Quality Council (MQC) Names Henry Ford Health System 2007 State Quality Award Recipient
7. AAPD to Present 2008 Henry B. Betts Award to International Human Rights Disability Advocate Eric Rosenthal
8. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
9. Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
10. Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers
11. Stella Mora Henry to Present The Eldercare Handbook at Aging in America Joint Conference of National Council on Aging & The American Society on Aging March 27-29
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Westaim announces 2008 year-end results 2Health News:Westaim announces 2008 year-end results 3Health News:Westaim announces 2008 year-end results 4Health News:Westaim announces 2008 year-end results 5Health News:Westaim announces 2008 year-end results 6Health News:Westaim announces 2008 year-end results 7Health News:Westaim announces 2008 year-end results 8Health News:Westaim announces 2008 year-end results 9Health News:Westaim announces 2008 year-end results 10Health News:Westaim announces 2008 year-end results 11Health News:Westaim announces 2008 year-end results 12Health News:Divided We Fail Pushes to Keep Health Care Reform as a Top Priority for Congress and the New Administration 2Health News:Divided We Fail Pushes to Keep Health Care Reform as a Top Priority for Congress and the New Administration 3Health News:Working With Robots May Help After a Stroke 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 3Health News:Dentists Often First to Spot Eating Disorders in Patients 2Health News:Dentists Often First to Spot Eating Disorders in Patients 3
Breaking Medicine Technology:Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 2Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 2Reportlinker Adds Medical Fiber Optics - A World Market Analysis 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 4Reportlinker Adds Medical Fiber Optics - A World Market Analysis 5Reportlinker Adds Medical Fiber Optics - A World Market Analysis 6Navigating in the ocean of molecules 9514 1Navigating in the ocean of molecules 9514 2Navigating in the ocean of molecules 9514 3NIH stimulus funding supports Emory biomedical scientists 9512 1NIH stimulus funding supports Emory biomedical scientists 9512 2NIH stimulus funding supports Emory biomedical scientists 9512 3NIH stimulus funding supports Emory biomedical scientists 9512 4Midwest Medical Aesthetics Helps Defy Nature and Wrinkles with Artefill 53946 1Midwest Medical Aesthetics Helps Defy Nature and Wrinkles with Artefill 53946 2Midwest Medical Aesthetics Helps Defy Nature and Wrinkles with Artefill 53946 3
Other Medicine Technology:Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 2Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 3Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 4Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 2Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 3Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 4Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 5Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 6Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 7